以LPV/r为基础的抗逆转录病毒治疗导致血脂异常研究进展

Research Progress on Dyslipidemia Caused by LPV/r Based Antiretroviral Therapy

克力芝属于蛋白酶抑制剂类的复方制剂,是目前常用的治疗艾滋病的高效抗逆转录病毒治疗(PIs类)药物,以克力芝为基础的初始抗病毒治疗方案在病毒学抑制和免疫恢复方面具有很好的疗效,但其导致血脂异常也比较常见。国内外均有以克力芝联合抗病毒治疗引起高甘油三酯血症及高胆固醇血症的报道。然而,对于预防性调节血脂方案,临床尚缺乏确切的循证医学证据。本文对克力芝导致血脂异常的研究进展进行了综述,为临床工作提供循证依据,最大程度地减少不良反应的发生。

Kaletra is a compound preparation of protease inhibitors.It is a highly effective antiretroviral therapy(PIs)drug commonly used to treat AIDS.The initial antiviral therapy based on Kaletra has high efficacy in virological inhibition and immune recovery,but it also leads to dyslipidemia.There are reports of hypertriglyceridemia and hypercholesterolemia caused by Kaletra combined with antiviral treatment at home and abroad.However,for the preventive lipid regulation program,clinical evidence is still lacking.This article reviews the research progress of Keletra induced dyslipidemia,which provides evidence-based recommendations and minimizes side effects.